A randomized, double-blind study of capecitabine plus tesetaxel versus capecitabine plus placebo as second-line therapy in subjects with gastric cancer

Trial Profile

A randomized, double-blind study of capecitabine plus tesetaxel versus capecitabine plus placebo as second-line therapy in subjects with gastric cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tesetaxel (Primary) ; Capecitabine
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms TESEGAST
  • Sponsors Genta (CEASED)
  • Most Recent Events

    • 31 Mar 2015 Planned number of patients changed from 260 to 580 as par M.D. Anderson Cancer Center record.
    • 31 Mar 2015 Status changed from recruiting to discontinued as per M.D. Anderson Cancer Center record.
    • 09 May 2012 Planned number of patients changed from 580 to 260 as reported in a Genta Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top